CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote

Capricor's stock is dropping after FDA briefing documents raised doubts about Deramiocel's effectiveness for Duchenne muscular dystrophy cardiomyopathy.

The FDA advisory committee will vote on the therapy's approval based on the data presented.

Deramiocel is intended to treat cardiomyopathy in patients with Duchenne muscular dystrophy.